Mental Health Clinics in Brielle, NJ Accepting Medicare
5 Mental Health Clinics found. Showing 1 - 5
 Symbol Of Hope Counseling, Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 400 Riverview Drive Suite 104, Suite 104, Brielle, NJ 08730 Phone: 732-290-5508 |
Rooted Works Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 800 Riverview Dr Ste 108, Brielle, NJ 08730 Phone: 201-723-6972 |
Talarico Consulting, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 617 Union Ave, Building 2, Suite 11, Brielle, NJ 08730 Phone: 908-600-6152 |
Tides Wellness Center Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 617 Union Ave Ste 10, Brielle, NJ 08730 Phone: 973-464-6985 |
Kristin M. O'gara, Msw, Lcsw, Llc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 617 Union Ave Unit 1-11, Brielle, NJ 08730 Phone: 732-513-8258 Fax: 732-223-1427 |
News Archive
Mesothelioma patients treated with radiation before surgery experience speedier recovery
Results of clinical research that treated mesothelioma with radiation before surgery show the three-year survival rate more than doubled for study participants afflicted with this deadly disease, compared to treating with surgery first.
MDs' reactions to pharma marketing influenced by brand, side effects
A study of pharmaceutical companies' marketing to physicians shows that doctors are most influenced by brand preference and marketing that addresses the problems of drugs with many side effects, according to the Management Insights feature in the current issue of Management Science, the flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS).
Mylan announces FDA approval for Cetirizine Hydrochloride tablets
Mylan Inc. has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride Tablets (OTC), 5 mg and 10 mg.
Results from Phase I dose-escalation study of AT-101 announced
Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).
Slushy spares kidney during partial nephrectomy
US researchers report the success and feasibility of a novel method of carrying out partial nephrectomy in kidney patients, using minimally invasive surgery.
› Verified 4 days ago